SCHEMBL2587536

SCHEMBL2587536

CN(C)S(=O)(=O)n1nc(Cl)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 5/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GAA P10253 2/20 0.33
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HTT P42858 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GLP1R P43220 2/20 0.31
TP53 P04637 1/20 0.31
GLA P06280 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30295506 0.81 MEN1 (0.34) MEN1KMT2AALDH1A1MCOLN3NPSR1
SCHEMBL2583804 0.78 PTGS2 (0.37)
SCHEMBL859854 0.69 MEN1 (0.37) MEN1KMT2AALDH1A1MCOLN3NPSR1
SCHEMBL417938 0.69 MEN1 (0.41) MEN1KMT2AALDH1A1GAASMN1; SMN2
SCHEMBL959784 0.65 MEN1 (0.37) MEN1KMT2AALDH1A1MCOLN3NPSR1
SCHEMBL18592843 0.60 HTT (0.35) MEN1KMT2ANPSR1SMN1; SMN2HTT
SCHEMBL3690645 0.60 PTGS2 (0.34) ALDH1A1GAAKDM4EL3MBTL1
SCHEMBL23804796 0.59 NPC1 (0.37) MEN1KMT2AALDH1A1NPSR1GAA
SCHEMBL12528570 0.59 MEN1 (0.40) MEN1KMT2AALDH1A1NPSR1GAA
SCHEMBL23459561 0.58 MAPT (0.57) MEN1KMT2AALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562015-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 EP disclosed
WO-2024026481-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
US-8586611-B2 Fungicidal carboxamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 2013-11-19 US disclosed
EP-1948649-B1 FUNGICIDAL CARBOXAMIDES DU PONT (US) 2013-06-26 EP disclosed
US-20110269712-A1 Fungicidal Carboxamides BISAHA JOHN JOSEPH 2011-11-03 US disclosed
EP-1948649-A2 FUNGICIDAL CARBOXAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2008-07-30 EP disclosed
WO-2007014290-A2 FUNGICIDAL CARBOXAMIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269712-A1 Fungicidal Carboxamides NAT1, PFAS, CHRM1 MEN1 773/4885KMT2A 404/4885ALDH1A1 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.